Clinical trials: People Who Inject Drugs
Hepatitis B
Hepatitis B Acceptability and Vaccination Incentive Trial
Aims: This prospective trial seeks to investigate the efficacy of a financial incentive in increasing the uptake and completion of the HBV vaccine series among people who inject drugs (PWID).
- Trial name
- HAVIT (NCT00744289)
- Testing
- Incentive condition
- Where
- Australia
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Prevention
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
The overarching goal of this study is to adapt and feasibility test an evidence-based strengths-based case management (SBCM) intervention for pre-exposure prophylaxis (PrEP) initiation, and examine preliminary efficacy of the…
- Trial name
- NCT05037513
- Testing
- SBCM-PrEP, CDC-PrEP
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Hilary L Surratt, PhD
HIV Seropositivity, Opioid-use Disorder
Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia
This pragmatic, multisite, implementation and effectiveness research evaluates a strategy to improve HIV treatment outcomes (increased rates of patients on ART with virological suppression, improved treatment retention and ART…
- Trial name
- NCT03987282
- Testing
- Enhanced usual care (EUC), Peer-based counseling
- Where
- Malaysia
- Volunteers
- 2 people
- Sponsor
- Yale University
HIV Infections
Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India
The goal of this study is to improve HIV care outcomes for people who inject drugs (PWID) in India. The study will implement a two-phase trial to evaluate whether HIV treatment outcomes (HIV viral suppression) in HIV infected…
- Trial name
- POINTER (NCT05165810)
- Testing
- Same-day ART initiation [experimental], Standard ART initiation [usual care], Community-based HIV care [experimental]
- Where
- India
- Volunteers
- 800 people
- Sponsor
- Johns Hopkins University
Hiv, Drug Use
Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)
This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART.
- Trial name
- RS-ART (NCT06541028)
- Testing
- Rapid-Start ART (RS-ART)
- Where
- 3 sites in Malaysia
- Volunteers
- 135 people
- Sponsor
- Yale University
Hepatitis C, People Who Inject Drugs
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care.
- Conditions
- Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
- Trial name
- NCT03214679
- Testing
- Accessible Care, Usual Care
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- City University of New York, School of Public Health
Hepatitis C, Diagnostic Self Evaluation
HCV Self-testing in Georgia
Self-testing with easy-to-use rapid diagnostic tests has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse populations…
- Trial name
- NCT04961723
- Testing
- (OraQuick® HCV Self-Test
- Where
- 6 sites in Georgia
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Stigma, Social, Drug Abuse Illicit
Lower Intersecting HIV-related Stigmas to Facilitate Treatment as Prevention (LIFT)
The purpose of this study is to reduce HIV transmission risk among people who inject drugs (PWID) through a multilevel intervention known as LIFT.
- Conditions
- Stigma, Social, Drug Abuse Illicit, HIV (Human Immunodeficiency Virus)
- Trial name
- LIFT (NCT07541131)
- Testing
- LIFT for People Who Use Drugs, LIFT for MMT Providers
- Where
- Kyrgyzstan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Hepatitis C Virus Infection
Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia
Hepatitis C virus infection is a major cause of chronic hepatitis, cirrhosis, and liver cancer. The risk of developing cirrhosis for people with chronic infection with the virus ranges from 15% to 30% over 20 years.
- Trial name
- HCV-PIWD (NCT06463912)
- Testing
- Does not apply
- Where
- Colombia
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Asociación Colombiana de Hepatología
HIV Positive People Who Inject Drugs
Rapid Antiretroviral Treatment Initiation With BIC/FTC/TAF in HIV-infected People Who Inject Drugs (PWID)
The goal of this clinical study is to evaluate the effectiveness, safety and patient experience of an integrated care pathway combining rapid antiretroviral (ART) initiation with BIC/FTC/TAF and peer navigation for treatment…
- Trial name
- BFTAFDU (NCT07004933)
- Testing
- bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
- Where
- 3 sites in Greece
- Volunteers
- 37 people
- Sponsor
- Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases
Bacterial Infection
: Bacterial Infections in Injecting Drug Users
Bacterial infections in people who inject psychoactive substances
- Trial name
- NCT04550767
- Where
- France
- Volunteers
- 117 people
- Sponsor
- University Hospital, Montpellier
HIV Infections, Drug Use
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and…
- Conditions
- HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder
- Trial name
- INTEGRA (NCT04804072)
- Testing
- Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care
- Where
- 5 sites in United States
- Volunteers
- 447 people
- Sponsor
- HIV Prevention Trials Network
COVID-19
A Spatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs
Conduct a study of people who use drugs (PWUD) perceptions of and access to COVID-19 vaccines as well as reasons for vaccine hesitancy/barriers
- Trial name
- NCT05769023
- Testing
- Intervention test
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Prevention
The PROTECT (PrEP Optimization Through Telehealth Care and Treatment) Trial
The expansion of HIV pre-exposure prophylaxis (PrEP) care has been endorsed as a key strategy for reducing new HIV infections, however, PrEP trials among people who inject drugs (PWID) are rare and uptake of PrEP has been…
- Trial name
- PROTECT (NCT06845774)
- Testing
- CDC PrEP with active referral, TelePrEP
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hilary L Surratt, PhD
HIV Infections, Opioid-Related Disorders
SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs
The purpose of this study is to develop and test a serious injection-related injections (SIRI) checklist aimed at increasing evidence-based treatment for rural people who use drugs (PWUD) including innovative, long-acting…
- Conditions
- HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP)
- Trial name
- SHAPE (NCT05480956)
- Testing
- SIRI Checklist, Enhanced Peer Recovery Coach, SIRI Checklist + Enhanced Peer Recovery Coach
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Opioid-use Disorder, HIV Prevention Program
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
The proposed study will be a 24-week intervention with a 12-month follow-up period to evaluate the impact of contingency management with stepped care to pre-exposure prophylaxis (PrEP) adherence and support services (CoMPASS) to…
- Trial name
- CoMPASS (NCT04738825)
- Testing
- Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)
- Where
- 6 sites in United States
- Volunteers
- 526 people
- Sponsor
- Yale University
Hepatitis C, Opioid Use
The Staying Safe Intervention
The growing population of young people who inject drugs (PWID) is at extremely high risk for HCV infection through the use of contaminated injection equipment, yet, to date, no behavioral intervention has been sufficiently potent…
- Trial name
- Ssafe (NCT03418636)
- Testing
- Staying Safe (Ssafe), Healthy Living
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- National Development and Research Institutes, Inc.
HIV Infections, Drug Use
Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial
The purpose of this study is to compare two implementation approaches [Standard Approach (SA) vs. Tailored Approach (TA)] for scaling-up the evidence-based systems navigation and psychosocial counseling integrated intervention…
- Trial name
- SNaPR01 (NCT03952520)
- Testing
- Standard Approach (SA), Tailored Approach (TA)
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
Human Immunodeficiency Virus
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
The purpose of this study is to assess the tolerability, adherence and efficacy of single tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with a history of injection drug use (IDU)…
- Trial name
- TAISTR (NCT02659761)
- Testing
- dolutegravir/abacavir/lamivudine
- Where
- Ireland
- Volunteers
- 33 people
- Sponsor
- University College Dublin
Chronic Hepatitis C, Intravenous Drug Usage
Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong
In the current era of highly effective direct acting antiviral (DAA) therapy, the remaining obstacles to elimination of chronic HCV infection are identification of the high-risk groups, linkage to continued care and prevention of…
- Trial name
- NCT03993925
- Where
- Hong Kong
- Volunteers
- 800 people
- Sponsor
- The University of Hong Kong